Twist Bioscience TWST 深 沪
已收盘 10-31 16:00:00 美东时间
32.89
+1.720
+5.52%
华盛通- 最 高34.08
- 今 开31.21
- 成交量 116.16万股
- 最 低 31.01
- 昨 收 31.17
- 总市值 19.85亿
- 52周最高 55.3325
- 市盈率 静 --
- 换手率 1.92%
- 52周最低 24.07
- 委 比 -69.88%
- 总股本 6036.09万
- 历史最高 214.07
- 量 比 0.93
- 振 幅 9.85%
- 历史最低 11.46
- 每 手 1
- 风险率 7.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cathie Wood Warns Wall Street Is Missing AI's Biggest Opportunity In Healthcare, Calling It 'Sleeper' Investment Poised For Massive Returns
Cathie Wood, CEO of Ark Invest, believes healthcare is the most profound application of AI and Wall Street is overlooking its potential.
10-15 18:17
美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
Twist Bioscience And Element Biosciences Launch Rapid Trinity Freestyle Workflow, Enabling End-to-End Sequencing In 5 Hours On AVITI Platforms
-- Launch of End-to-End Workflow for AVITI and AVITI24™ Enabling Sample to Sequencer in as Little as Five Hours ---- Twist Gains Exclusive Access to the new, co-developed Trinity Freestyle™ Sequencing
10-06 20:12
Kuehn Law Encourages Investors of Twist Bioscience Corporation to Contact Law Firm
NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: ...
09-16 01:08
投资者正获利了结？ARK创新ETF(ARKK.US)遭大规模赎回 “木头姐”伍德仍在逢低买入更多股票
由“木头姐”伍德管理的ARK创新ETF今年以来表现亮眼，但近期资金流向显示投资者可能在获利了结
08-20 06:00
Cathie Wood's 'Apocalypse Squad' Play? Ark Scoops Up $14.2 Million Worth Of Robinhood Stock
Ark Invest, led by Cathie Wood, made significant trades on Monday, acquiring shares of Robinhood and Deere & Co. Other key trades also took place.
08-19 09:41
全球生物开发者大会圆满落幕，赋能合成生物新未来
（来源：辰珵） 北京，2025年8月11日——为期三天的第十二届中国基因工程机器交流大会（CCiC）暨第二届全球生物开发者大会（Synbiopunk）于8月...
08-18 10:11
Twist Bioscience Turns The Tide: Q3 Sales Jump, Beats Earnings
Twist Bioscience beat Q3 revenue estimates, improved gross margins, and narrowed its full-year outlook while forecasting EBITDA breakeven fiscal 2026.
08-05 03:52
Twist Bioscience Sees Q4 Sales $96.000M-$98.000M vs $99.174M Est
For the fourth quarter, Twist expects: • Total revenue of approximately $96 million to $98 millionSynBio revenue of approximately $38 million to $39 millionNGS revenue of approximately $52 million to $53
08-04 19:21
Twist Bioscience beats top-line and bottom-line estimates; initiates Q4 and updates FY outlook
Twist Bioscience press release (NASDAQ:TWST): Q3 GAAP EPS of $0.34 beats by $0.91. Revenue of $96.1M (+17.9% Y/Y) beats by $0.46M. Adjusted EBITDA: Adjusted EBITDA for the third quarter of fiscal 2025...
08-04 19:21
